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Background/Aims
This study was designed to investigate the possibility that the enhanced nociceptive responsiveness associated with canabonoid 
type 1 receptors (CB1Rs) and identify its role in mediating visceral hypersensitivity induced by chronic restraint stress.
Methods
Rats were exposed to daily partial restraint stress or sham partial restraint stress with intraperitoneal injection of the vehicle, 
CB1R agonist or antagonist for 4 consecutive days. We tested the visceromotor reflex to colorectal distention at day 0 and 
5. Reverse-transcription polymerase chain reaction and Western blot were used to assess the expression of CB1Rs.
Results
Intraperitoneal CB1 agonist (ACEA) injection significantly diminished (p < 0.05) the enhanced visceromotor reflex to colorectal 
distention at day 5 in stressed rats. Change in electromyogram response after ACEA over baseline, at pressure of 40 mmHg 
(+13.3 ± 2.2), 60 mmHg (+15.3 ± 2.8) and 80 mmHg (+17.0 ± 4.0) were much lower than in the control animals, which 
were +35.9 ± 5.1, +41.1 ± 6.3 and +54.1 ± 9.6, respectively. Whereas, CB1 antagonist (SR141716A) had an opposite effect. 
Compared with control group, the change in electromyogram response after SR141716A over baseline was significantly en-
hanced (p < 0.05) for the distending pressure of 40 mmHg (+56.0 ± 10.3), 60 mmHg (+74.6 ± 12.3) and 80 mmHg (+82.9
± 11.0), respectively. Reverse-transcription polymerase chain reaction and Western blotting demonstrated the stress-induced 
up-regulation of colon CB1Rs (p < 0.05).
Conclusions
Our results suggest there is a key contribution of peripheral CB1Rs involved in the maintenance of visceral hyperalgesia after 
repeated restraint stress, providing a novel mechanism for development of peripheral visceral sensitization.
(J Neurogastroenterol Motil 2010;16:281-290)
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Introduction
For centuries, different preparations of Cannabis plants have 
been used for the treatment of gastrointestinal (GI) disorders 
such as spasmic pain, gastroenteritis and diarrhea.
1 Nowadays, a 
growing body of literature indicates substances acting on canna-
binoid receptors alter secretion and motility of the gut,
2,3 and have 
antinociceptive or antihyperalgesic properties.
4 This makes them 
an attractive target for GI functional disorders, such as irritable 
bowel syndrome (IBS). IBS is a typical of such disorders, which 
have visceral sensitivity, autonomic nervous system dysfunction 
and can be induced by mental stress .
5 So we associated those fac-
tors into our experiment, tried to figure out whether interfering 
into the mental stress can remedy the stress induced visceral 
hypersensitivity.
5 Upon external psychological stress insults, sev-
eral different cellular pathways are activated in the intestinal tract, 
leading to a pathological state.
6 And, the discovery of the endoge-
nous cannabinoid (endocannabinoid) system
7 provided new in-
sights into a neuromodulatory scheme, portends better ex-
planations, and treatments for, a wide variety of previously in-
tractable disorders, particularly painful conditions,
8,9 were pro-
mising.
Recent evidence obtained in model of neuropathic pain 
showed greater effects of cannabinoids reducing sensitivity to 
pain and boosting endurance, strongly suggesting cannabinoid 
receptors have capable of anti-nociceptive.
10 Based on cumulated 
literature of searches about involvement of cannabinoid system in 
the pathophysiology of IBS, an underlying clinical endocannabi-
noid deficiency that implicated a plausible target for novel thera-
pies for IBS was suggested.
11 In animal model, experiment mus-
cle tone has been demonstrated to be under tonic endocannabi-
noid control,
12 especially in treatment of spasticity, cannabis ex-
tracts have already proven efficacious.
13,14 To date, two cannabi-
noid receptors have been isolated and cloned. Activation of can-
nabinoid type 1 receptors (CB1Rs) was shown to modulate sev-
eral functions in the GI tract, including gastric secretion, gastric 
emptying and intestinal motility,
15 while CB2Rs are mainly lo-
cated in immune cells.
Cannabinoid act at many points within the brain-gut axis, in-
fluencing GI activity through their actions centrally or on ex-
trinsic primary afferent nerves. Among the roles of the endo-
cannabinoid system at different level, its analgesic action at spinal 
and peripheral levels has been largely documented.
4 Outside of 
the CNS, high densities of CB1Rs are found in the enteric nerv-
ous system, sympathetic and sensory nerve, which suggests the 
essential effects of cannabinoids in the peripheral primary 
afferent. These effects are often different from those mediated by 
actions directly on the enteric nervous system. So it’s meaningful 
to investigate the involvement of CB1Rs in the peripheral. It has 
been shown that action of CB1 attenuates colonic-inflammation 
induced visceral hyperagesia.
16 
Recently, chronic intestinal inflammation model experiment 
reports the up-regulation or sensitization of cannabinoid re-
ceptors in the small intestine,
17 but the antihyperalgesic action of 
cannabinoid is not well established. Only a limit numbers of stud-
ies indicated the modulation role of CB1Rs in non-inflammatory 
visceral hypersensitivity model. CB1Rs mediating the analgesic 
effect on visceral pain induced by colorectal distension was shown 
in a recent research.
18 It might helpful to determine whether there 
are any changes in CB1Rs expression associated with underlying 
pathology. In the present investigation, we examined the role of 
the CB1Rs after partial restraint stress insults in the colon and in-
dicated this system provides intrinsic protection against stress in-
duced visceral hyperalgesia. 
Materials and Methods
1. Animals
Adult male Sprague-Dawley rats (250-275 g) were pur-
chased from Experimental Animal Center of Tongji Medical 
School (Wuhan, P. R. China). Animals were maintained on a 
normal light-dark cycle, housed in pairs or singlely, and were 
kept in a regulated environment (20-25
oC). They were provided 
with food and water ad libitum. All protocols were approved by 
the Animal Care and Use Committee of Union Hospital of 
Tongji Medical College. All experiments were performed during 
the same period of the day (between 10:00 and 12:00) to mini-
mize any influence of circadian rhythms.
2. Experimental design
A total of 6 groups of 8 rats were included in this study. 
Acclimation to the experimental conditions was performed for 3 
days preceding the start of the experiment. Each day, animals 
were transported to the testing room and placed for 30 minutes in 
the Plexiglas cylinders used for colorectal distension (CRD) 
experiments. On day 0, a baseline response to CRD was eval-
uated (CRD #1). From day 1 to day 4, rats were submitted daily 
to either 2-hour partial restramint stress (PR) for the stress group The Role of Cannabinoid 1 Receptor in Visceral Hypersensitivity
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or to 2-hour sham PR for the control group, Then the response to 
CRD was measured again at day 5 (CRD #2), and in order to 
check for the acute involvement of CB1 on visceral hyperalgesia, 
the rats were treated with CB1R agonist, antagonist or vehicle. If 
the endogenous cannabinoid system plays an important role in 
the visceral sensory pathway protection from PR induced visceral 
hyperalgesia, it is conceivable that activation or block of cannabi-
noid receptors during CRD process might diminish or ex-
acerbate the hypersensitivity. The different samples collected for 
reverse-transcription polymerase chain reaction (RT-PCR) and 
Western blotting analysis were taken from animals that had not 
undergone CRD to avoid the potential bias.
3. Partial restraint stress procedure
Stress effects were studied using the wrap PR model.
19 
Animals were lightly anaesthetized with ethyl ether, and their fore 
shoulders, upper forelimbs and thoracic trunk were wrapped in a 
confining harness of paper tape to restrict, but not to prevent, 
body movements. Then, the animals were placed in their home 
cage for 2 hours. The rats recovered from ethyl ether within 2-3 
minutes and immediately moved about in their cages, with the re-
stricted mobility of their forelimbs preventing grooming 
behavior. Control sham PR animals were anaesthetized but not 
wrapped and allowed to move freely in their cages. The PR at 
room temperature used here is a mild and non-ulcerogenic stres-
sor which reproduces the symptoms associated with stress related 
colonic dysfunction in humans, suggesting that it may be a suit-
able model for studying the effect of stress on the GI tract.
4. Visceral nociceptive response to chronic PR stress: 
effect of peripheral treatment with the CB1R agonist 
and antagonist
The CB1R agonist ACEA [N-(2-Chloroethyl)-5Z, 8Z, 11Z, 
14Z eicosatetraenamide] and CB1R antagonist SR141716A [N- 
(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)- 
4-methyl-1H-pyrazole-3-carboxamide], purchased from Tocris 
Cookson Inc (Bristol, UK) They were dissolved in vehicle sol-
ution (1 drop of Tween-80 in 3 mL 2.5% dimethylsulfoxide in 
saline) and injected 1 hour after the end of PR from day 1 to day 
4. Vehicle solution was used in control experiments. ACEA, 
SR141716A and vehicle were tested in both chronically stressed 
and sham stressed animals. The dose of 5 mg/kg and 3 mg/kg 
body weight was selected based on published reports respec-
tively.
20,21
5. Assessment of visceromotor response to colorectal 
distention
1) Colorectal distention
Taking former as standard, the stimulus was induced by dis-
tention of descending colon and rectum, which has been estab-
lished available, our procedure was after the formula.
22 Animals 
were lightly anesthetized with halothane, then a pair of silver elec-
trodes was pricked into the external oblique muscle, just superior 
to the inguinal ligament and inflexible plastic balloon (7 cm long 
and 2 cm wide) lubricated with liquid paraffin oil (Sigma, MO, 
USA) was inserted intra-anally into the descending colon (after 
the distal part of the rectum was gently cleared by massage), posi-
tioned with the tip 1 cm proximal to the anus, and secured in 
place by taping the balloon catheter to the base of tail. Once re-
covered from anesthesia, animals equipped with the balloon were 
placed in a Plexiglas cylinder for 30 minutes before the CRD 
procedure was initiated. Electromyogram (EMG) recording was 
done as follows: 20 seconds before CRD (baseline), 20 seconds 
during CRD and 20 seconds after termination of CRD. Each in-
tensity grade of phasic CRD (20, 40, 60 and 80 mmHg) lasted 
20 seconds and interval of stimulus was 4 minutes; each pressure 
was tested 3 times. 
2) Recording
The catheter, which was fixed a balloon on one end, was then 
connected to an air pump via a Y connector on the other end. The 
balloon pressure, which represents intracolonic pressure, was 
continuously monitored online with a computer. EMG activity 
surpassing the preset threshold value 300 IV during the balloon 
inflation period was amplified, filtered (1,000-4,000 Hz), and 
digitized (sampling at 200 Hz) using a program written in 
RM6240B (Chengdu Instruments, Sichuan, China). The EMG 
was quantified with frequency. Results are presented as the 
means ± SD. Animals showing an EMG signal/noise ratio < 
0.05 were excluded from the study.
6. Collection of distal colon, proximal colon, and distal 
small intestinal samples for CB1R expression analysis
The different samples collected for molecular analysis were 
taken from animals that had not undergone surgery or CRD to 
avoid the potential bias that this procedure may induce regarding 
neurotransmitter production or release. Animals were subjected 
either to PR or sham PR stress for 2 hours daily for 4 consecutive 
days. On day 5, animals were killed, distal colon positioned with 
the tip 1 cm proximal to the anus, proximal colon positioned 1cm Lei Shen, et al
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distant from ileocecal junction and distal intestinal positioned 1 
cm proximal to the ileocecal junction. And then segments 2-3 cm 
long of distal colon, proximal colon and distal small intestine were 
quickly removed and then placed either in RNA later solution for 
RT-PCR experiments or frozen on dry ice for Western blotting 
analysis.
1) Detection of CB1R messenger RNA expression 
Preparation: Weighted 50 mg tissues of each species, and 
then homogenized in 1mL of TRIzol Reagent (Invitrogen Inc, 
Carlsbad, CA, USA). Incubated the homogenized samples to 
15
oC for 5 minutes in eppendorf tubes. Added 0.2 mL chloro-
form into each eppendorf tube. Caped the tubes and shaked vigo-
rously by hand for 15 seconds and then incubated them to 15
oC 
for 3 minutes. Centrifugated at 12,000 × g for 15 minutes at 
4
oC. Transfered the colorless upper aqueous phase to a fresh new 
tube. Then added 0.5 mL of isopropyl alcohol into each tube, in-
cubated to 15
oC for 10 minutes. Centrifugated at 12,000 × g for 
10 minutes at 4
oC. A gel-like pellet on the side and bottom of the 
tube visible was RNA. Removed the supernatantand Washed the 
RNA with 1 mL of 75% ethanol, and then centrifuged at 7,500 
×g  f o r  5  m i n u t e s  a t  4
oC. Air dried the RNA. The RNA was dis-
solved in 10 μL RNase-free water and measured by spectropho-
tometer analysis at 260 nm.
(1) Reverse transcriptase
Added 2 μg of RNA and 0.5 μg of Oligo dT18, and ribonu-
clease-free water to a final volume of 10 μL. Tubes were heated 
to 70
oC for 5 minutes and then fast cooled on ice to prevent sec-
ondary structure from reforming. Then spined briefly to collect 
the solution at the bottom of the tube. RNA was transcribed to 
cDNA by a reverse transcriptase in a total 25 μL RT reaction sol-
ution containing 5 μL 5 × Reverse Transcriptase Buffer, 5 μL 
dNTP (10 mM each, Promega, Shanghai, China) 25 unites 
RNase Inhibitor, 200 units MMLV-RTase (Promega). Shaked 
up the mixture, and then incubated it to 37
oC for 60 minutes for 
random primers.
(2) Polymerase chain reaction
The system was composed of 15.9 μL H2O, 0.3 μL of for-
ward primer, 0.3 μL of reverse primer, 1.0 μL dNTP, 2.5 μL 
Mg,
2+ 2.5 μL of 10×Buffer, 2.0 μL of cDNA and 0.5 μL of 
Taq DNA polymerase in a total volume of 25 μL. The primer of 
CB1R was 5’-CCTGGTTCTGATCCTGGTGG-3’; 5’-GTT-
GTTGGCGTGCTTGTGC-3’ (283 bp, gi: 52421334). And 
the primer of β-actin was 5’-AGGGAAATCGTGCGTGAC-3’; 
5’-ACCCAGGAAGGAAGGCT-3’ (189 bp, gi:13592132). They 
were designed by primer 5.0. The reaction condition was first 
95
oC for 5 minutes to activate Taq DNA polymerase, followed by 
denaturation at 95
oC for 30 seconds, annealing 57
oC (CB1R)/ 
48
oC (β-actin) for 30 seconds and extension at 72
oC for 30 
seconds. The PCR was run for 35 cycles and finally elongated at 
72
oC for 7 minutes. The PCR products were detected by ethi-
dium bromide staining on a 1% agarose gel, together with DNA 
Marker DL2000 (Takara, Dalian, China). And then total gray 
was evaluated by bandscan 4.3 (Glyko, Novato, CA, USA). The 
ratio of CB1Rs and β-actin corresponding were recorded.
2) Detection of CB1R protein expression
To minimize the error, standard the weight of tissue to 200 
mg. Tissues were homogenized in ice-cold lysis buffer solution 
(pH 7.4) containing a mixture of proteinase inhibitors (50 mM 
Tris-HCl, 100 mM NaCl, 15 mM sodium pyrophosphate, 50 
mM sodium fluoride, 1 mM sodium orthovanadate, 5 mM eth-
yleneglycol bis (2-aminoethylether) tetraacetic acid (EGTA), 5 
mM ethylene diamine tetraacetic acid (EDTA), 1 mM phenyl-
methylsulfonyl fluoride, 1 μM microcystin-LR, 1 μM okadaic 
acid, 0.5% TritonX-100, 2 mM benzamidine, 60 μg/mL aproti-
nin and 60 μg/mL leupeptin) to avoid degradation of proteins. 
After centrifugation with 12,000×g at 4
oC for 10 minutes, the 
supernatant was then assayed for total protein concentration us-
ing the Bio-Rad Bradford Protein Assay it. Equal amounts of 
protein in sample buffer (1% sodium dodecyl sulfate, 10% glyc-
erol, 100 mM Tris, 0.05% biphenyl blue and 5% 2-mercaptoe-
thanol) were denatured, and then samples containing equal 
amount of protein were separated by 12% sodium dodecyl sul-
fate-polyacrylamide gel electrophoresis (SDS-PAGE) through 
electrophoresis and transferred to a polyvinyldine difluoride 
membrane. The membranes were blocked with in 5% nonfat 
milk in Tri-buffered saline (TBS) containing 0.2% Tween-20 
(TBS-T) for 1 hour and were incubated with CB1R rabbit anti-
serum (catalog AB3558, Abcam, Cambridge, USA) at a final di-
lution (1:250) for overnight at 4
oC. Washed in TBS buffer three 
times for 10 minutes, incubated for 1 hour with goat anti-rabbit 
IgG conjugated with alkaline phosphatase (1:2,000, Sigma) in 
TBS-T, washed in TBS-T buffer three times for 10 minutes 
again, then incubated in chemiluminescent substrate solution 
(ECL, Pierce, Rockford, IL, USA). The blots were scanned and 
imported into the Image Pro program (5.1 version, Media 
Cybernetics, Bethesda, MD, USA) to measure the integral opti-
cal density of individual bands. The intensity of immunoreactive 
bands of interest was quantified and the data were normalized 
with the data of α-actin of controls in the same blot. The same ex-
periments were repeated three times, and results are presented as The Role of Cannabinoid 1 Receptor in Visceral Hypersensitivity
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Figure 1. Effect of peripheral administration of the cannabinoid type 1 receptor (CB1R) agonist/antagonist on the electromyograpghy (EMG) to 
colorectal distension (CRD). (A) Effect of peripheral administration of the CB1R agonist/antagonist on the EMG to CRD of partial restraint 
stressed rats (day 5). EMG amplitude expressed as mean change from baseline after treatment with vehicle, ACEA or SR141716A in rats exposed 
to repeated partial restraint stress. Intraperitoneal injection of ACEA abolished the chronic stress-enhanced EMG to CRD compared with vehicle 
at the pressures of distention of 40, 60 and 80 mmHg. Meanwhile, intraperitoneal injection of SR141716A had an exacerbated effect to the chronic 
stress-enhanced EMG to CRD compared with vehicle at the pressures of distention of 40, 60 and 80 mmHg. (B) Effect of peripheral administration 
of the CB1R agonist/antagonist on the EMG to CRD of sham PR rats (day 5). EMG amplitude expressed as mean change from baseline after 
treatment with vehicle, ACEA or SR141716A in rats exposed to chronic sham PR. ACEA or SR141716A did not affect the EMG response after 
chronic sham PR compared with vehicle. Data are expressed as mean ± SE, n = 8 in each group, *p < 0.05 significantly different compared with 
vehicle, 1-way ANOVA.
means ± SD.
7. Statistical methods
EMG amplitudes were represented as percentage for the 
normalized reason. According to Bradesi’s practice, is the per-
centage between highest and baseline distension. Then the value 
of each rat of groups will be averaged.
23,24 The effect of stress 
and/or pharmacologic treatment on the EMG response to CRD 
within one group of animals was analyzed by comparing the 
post-stress or post-treatment measurements with the baseline or 
pretreatment values at each distention pressure using re-
peated-measures 2-way ANOVA followed by Bonferroni posttest 
comparisons. We have presented the data showing the EMG re-
sponse at day 5 for rats treated with compound or vehicle ex-
pressed as the mean change from baseline for different pressures 
of distention. This method of analysis has been previously vali-
dated in a similar model of EMG measurement in response to 
CRD.
24 These data were analyzed using Student’s t test.
Data for the expression of CB1Rs obtained from RT-PCR 
and Western blot between stressed and control groups were com-
pared using an unpaired t test.
Results
1. Visceral hyperalgesia was reduced by administration of 
the potent cannabinoid agonist ACEA
As shown in Figure 1A, ACEA abolished the stress-induced 
increase of the EMG compared with vehicle (Dunnett’s test for 
multiple comparisons after ANOVA, 40 mmHg, p = 0.028; 60 
mmHg, p = 0.036; 80 mmHg, p = 0.007). ACEA application 
reduced the EMG response to a level similar to Sham-PR group 
(change in EMG response after ACEA over baseline, +13.3 ± 
2.2 at 40 mmHg, +15.3 ± 2.8 at 60 mmHg and +17.0 ± 4.0 
at 80 mmHg), while no significant effect (p > 0.05) of vehicle 
application was observed (change in EMG response after vehicle 
over baseline, +35.9 ± 5.1 at 40 mm Hg, +41.1 ± 6.3 at 60 
mmHg and +54.1 ± 9.6 at 80 mmHg). Meanwhile, in the dis-
tension pressure of 20 mmHg, neither enhanced nor reduced re-
sponse was shown.
To determine the effect of the CB1R agonist in controls, we 
tested the response to ACEA or vehicle injection in animals pre-Lei Shen, et al
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Figure 2. Representative reverse-transcription polymerase chain 
reaction (RT-PCR) for cannabinoid type 1 receptor (CB1R) in distal 
colon, proximal colon and distal small intestine. Band of 1, 2 and 3 
represent PCR for CB1R in distal colon, proximal colon and distal 
small intestine from the rats of the sham partial restraint stress (PR) 
group; 4, 5 and 6 represent PCR for CB1R in distal colon, proximal 
colon and distal small intestine from the rats of the PR group. 7, 8 and 
9 represent PCR for β-actin of controls in distal colon, proximal 
colon and distal small intestine from the rats of the sham PR group; 
10, 11 and 12 represent PCR for β-actin of controls in distal colon, 
proximal colon and distal small intestine from the rats of the PR 
group.
Figure 3.  Expression of cannabinoid type 1 receptor (CB1R) in 
distal colon, proximal colon and distal small intestine following 
repeated partial restraint stress (PR). Levels of mRNA for CB1R 
measured by reverse-transcription polymerase chain reaction 
(RT-PCR). We observed a significantly higher level of CB1R 
mRNA in samples from chronic PR stress rats compared with 
control. Data are expressed as the relative CB1R PCR product to that 
of the housekeeping gene β-actin, mean ± SEM, n = 8 in each 
group.
Table 1. Change in Electromyogram Response Over Baseline of Control Groups
Groups 20 mmHg 40 mmHg 60 mmHg 80 mmHg
Sham PR + Vehicle -2.8 ± 6.9 -5.4 ± 4.3 -6.1 ± 7.3  6.1 ± 3.2
Sham PR + SR141716A  1.1 ± 1.7 -6.1 ± 2.7  7.4 ± 5.8  9.7 ± 6.5
Sham PR + ACEA  0.7 ± 4.5  2.9 ± 2.3  7.3 ± 8.5 12.6 ± 3.4
p-value 0.823 0.113 0.341 0.629
PR, partial restraint stress; SR14716A, CB1 antagonist; ACEA, CB1 agonist.
Data are presented as mean ± SD.  
viously subjected to repeated sham PR. Compared with baseline, 
repeated exposure to sham PR had no significant effect on the 
EMG to CRD. As shown in Figure 1B and Table 1, injection of 
vehicle or ACEA did not change the response to CRD. 
2. Pharmacological blockade of CB1 signaling increases 
severity of induced hypersensitivity
Treatment with SR141716A induced stronger visceral hy-
peralgesia than treatment with vehicle. This was shown by the 
number of abdominal contractions to CRD #2, for the distend-
ing pressure of 40 mmHg (+56.0 ± 10.3), 60 mmHg (+74.6
± 12.3) and 80 mmHg (+82.9 ± 11.0) (p = 0.047, 0.008 and 
0.030, respectively; Fig. 1A). It reveals a more severe visceral hy-
persensitivity in SR141716A-treated rats, with significant in-
crease in numbers of abdominal contractions, as compared with 
vehicle-treated controls. In comparison with vehicle, for distend-
ing pressures of 20 mmHg, the compounds tested did not modify 
these EMG response induced by PR.
3. PR Stress significantly enhanced CB1R expression
1) Semiquantitative RT-PCR for CB1R
CB1R mRNA was expressed in the distal colon, proximal co-
lon and distal small intestine, and the authenticity of the PCR 
product was verified by sequencing analysis (Fig. 2). We found 
significant increased expression for CB1R mRNA in samples 
from chronically partial restraint stressed animals compared with The Role of Cannabinoid 1 Receptor in Visceral Hypersensitivity
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Figure 5. Expression of cannabinoid type 1 receptor (CB1R) in 
distal colon, proximal colon and distal small intestinal following 
repeated partial restraint stress (PR). Levels of CB1R protein 
measured by Western blotting. A significant increase in the level of 
CB1R protein in samples from chronic PR stress rats compared with 
control was observed. Data are expressed as normalized optical 
density, mean ± SEM, n = 8 in each group.
Figure 4. Representative Western blotting for cannabinoid type 1 
receptor (CB1R) in distal colon, proximal colon and distal small 
intestine. The band of 1, 2 and 3 represent Western blotting for 
CB1R in distal colon, proximal colon and distal small intestine from 
the rats of the sham partial restraint stress (PR) group; 4, 5 and 6 
represent Western blotting for CB1R in distal colon, proximal colon 
and distal small intestine from the rats of the PR group.
control (semiquantitative analysis, 0.79 ± 0.13, 0.66 ± 0.10 and 
0.88 ± 0.10 in sham PR; 1.46 ± 0.21, 1.40 ± 0.14 and 1.44 ± 
0.17 in PR; p = 0.019, 0.001 and 0.013, respectively; Fig. 2 and 
3).
2) CB1R protein expression in intestine
Western blot analysis in control and PR stress groups re-
vealed a ~60 kDa band corresponding to the CB1R protein 
(Fig. 4). Optical density analysis of blots showed significant 
higher expression of the CB1R in the stress group compared with 
control (p = 0.0134) (0.70 ± 0.11, 0.67 ± 0.08 and 0.73 ± 
0.09 in sham PR; 1.35 ± 0.28, 1.15 ± 0.17 and 1.16 ± 0.16 in 
PR; p = 0.044, 0.023 and 0.035, respectively). A 31% reduction 
was observed in the PR group compared with control (Fig. 5).
Discussion
The synchronous modulation between cannabinoid system 
and visceral hypergesia reflects a directly participation of canna-
binoid system in the maintenance of physical sensation. Based on 
self-care and stress research, it is reasonable to propose that our 
bodies contain naturally occurring properties, including endo-
cannabinoid auto-regulation, maintain our healthy such as stress 
reduction.
25 These data show a protective role of the CB1Rs, in-
dicating an early and important physiological step during 
self-protection of the stress-induced hypersensitivity.
1. Pharmacology properties of CB1R in rats with visceral 
hyperalgesia induced by PR
Pharmacological stimulation of cannabinoid receptors in-
duced a reduction of experimental hyperalgesia, whereas selective 
antagonism of these receptors has the opposite effects, suggesting 
the presence of endocannabinoid tone. Previous reports have 
shown an inhibitory effect of different CB1R agonists on visceral 
hyperalgesia in several animal models of peripheral colonic 
sensitization. For example, endocannabinoids exert a homeostatic 
function at the level of visceral perception, gut motility, in-
flammation and endothelial damage in inflammation.
26-28 A col-
lection of previously published material pointed to CB1R play an 
important role in antihyperalgesic. Our findings support it and 
assume the process through visceral afferent pathway by control 
the expression of the receptors. The occurrence of hyperalgesia in 
the small or the large intestine is widely accepted. The balance be-
tween pro- and anti-visceral hyperalgesia within intricate surveil-
lance network determines the outcome of the pathological proc-
esses of IBS.
29 This result is consistent with previous reports dur-
ing which colonic inflammation enhanced the antinociceptive ac-
tion of CB1R agonists, and activates an endogenous, CB1R 
mediated, antinociceptive pathway,
16 suggesting a higher activa-
tion of gut endogenous cannabinoid system in the pathological 
state. Similar changes have been also previously reported in the 
setting of enhanced sensation models, in which repeated admin-
istration of cannabinoid agonist, through peripheral CB1Rs, pro-
duced a short- and longer- term attenuation of tumor-evoked hy-
peralgesia,
30 and inflammation pain relieving.
31 
The decrease in sensitivity to CRD induced by the CB1R ag-
onist is supported by several anatomical data. CB1Rs, identified 
by western-blotting, have been shown to be involved in the non-
cholinergic control of intestinal motility.
32 In a recent study, the 
stimulation or inhibition of CB1R alter the afferent intestinal 
nerve sensitivity to bradykinin, serotonin and noxious mechanical 
distension.
33 Consistent with this hypothesis, contractility of Lei Shen, et al
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smooth muscle to cholinergic or tachykinergic stimuli is in-
creased in the early stages and decreased in the later stages of in-
flammation
34,35 which confirm the involvement of cannabinoid 
system, through neuro-mechanism, in the visceral hypersen-
sitivity modulation. Our results indicate that endogenoise canna-
binoid are involved in this feedback mechanism though CB1Rs 
to limit chronic stress-induced hypersensitivity. The activation of 
serotonin 1A could inhibit the visceral motor induced by visceral 
pain, but had no effect to autonomic cardiovascular of responses 
to colorectal distension in rats, which imply us peripheral sys-
temic administration might have in adequate central exposure.
36 
So in our research, the modulation effects were mainly due to the 
activation of peripheral cannabinoid receptors.
Intracolonic pressure of ≤ 20 mmHg would be perceived as 
non-nociception in normal rats, which pathway to the CNS was 
different from the nociceptive stimulation.
37 In our result, 20 
mmHg has no significant changes between groups. Thus we 
speculated that non-nociception pathway was not involved in the 
hypersensitivity induced by chronic PR.
2. Stress-induced up-regulation of CB1R expression in 
the large and small intestine
In the present study, involvement of the endogenous canna-
binoid system in the modulation of the acute phase of restrain 
stress-induced hyperalgesia is further supported by the increased 
levels of transcripts coding for CB1Rs in rats exposed to repeated 
restraint stress. Recent data indicate a protective function of 
up-regulated endocannabinoid levels in colitis.
38,27 In rats and 
guinea pigs, besides an expression in cholinergic myenteric neu-
rons, a close association between CB1R immunoreactivity and fi-
bers labeled for a synaptic protein has been described, suggesting 
a role in the modulation of transmitter release.
39 Similarly, ex-
pression of CB1Rs has been found to be up-regulated in rats dur-
ing an experimental intestinal inflammation.
26,40
CB1-deficient mice or wild-type mice treated with the CB1R 
antagonist Rimonabant display a stronger experimental colitis 
than controls.
26 Endocannabinoid levels are also increased in dif-
ferent models of neuropathic pain.
41-43 It is now well established 
that CB1R participate in many aspects of the neuroimmune re-
sponse triggered by intestinal infection or inflammation. 
However, the mechanisms underlying increased CB1R ex-
pression observed in association with peripheral inflammation is 
incompletely understood. Thus, present study show the evidence 
that neurons that express low levels of CB1Rs in basal conditions 
start to express this receptor to enhance endocannabinoid signa-
ling. These changes may not only serve as potential therapeutic 
targets for IBS, but also lead to the identification of novel regu-
latory mechanisms involved in pathophysiology. In the gut, 
CB1Rs are likely to be activated by the products of inflammation 
in IBS, and, through its up-regulation, may contribute to feed-
back mechanism of hypersensitivity. This finding provides evi-
dence that the levels of CB1Rs are strictly related to active 
hypersensitivity.
The early alterations in abdominal contractile response to col-
orectal distension of agonist/antagonist treated rats and the in-
creased levels of CB1R mRNA in myenteric plexuses of en-
hanced sensation colons seem to point to an important, if not pre-
dominant, function of the endogenous cannabinoid system at pe-
ripheral sites. Use of central administration of drugs or, con-
versely, of cannabinoid agonists and antagonist unable to cross 
the blood-brain barrier will help to clarify this important issue.  
In conclusion, this study shows the endogenous cannabinoid 
system is physiologically involved in the protection against ex-
cessive hyperalgesia in the colon, strongly suggesting modulation 
of the physiological activity of the endogenous cannabinoid sys-
tem during stress might be a promising therapeutic tool for the 
treatment of several diseases characterized by hyperalgesia of the 
GI tract.
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